<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33553">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01944319</url>
  </required_header>
  <id_info>
    <org_study_id>75505-01</org_study_id>
    <nct_id>NCT01944319</nct_id>
  </id_info>
  <brief_title>Meropenem Dosage Strategy Based on PPK Model</brief_title>
  <official_title>Clinical Evaluation of a Meropenem Dosage Strategy Based on a Population Pharmacokinetic-pharmacodynamic Model in Lower Respiratory Tract Infection Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingtao Zhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical and economical benefits of a meropenem dosage strategy based on a
      population pharmacokinetic(PPK)-pharmacodynamic(PD) model in lower respiratory tract
      infection patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Subjects:lower respiratory tract infection patients

        -  Study design:randomized control study.The patients in study group will accept meropenem
           therapy with the regimen decided by a software developed from population
           pharmacokinetic model and clinical pharmacodynamic parameter. The patients in control
           group will accept meropenem therapy with the regimen decided by attending physician.

        -  Primary endpoint: clinical successful rate of meropenem therapy. THe clinical
           efficiency of meropenem therapy will be evaluated one week later from stop of meropenem
           therapy.

        -  Second endpoint:duration of meropenem therapy and amount of used antibiotics.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical success rate</measure>
    <time_frame>One week after antibiotic therapy finished.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The clinical success or failure of meropenem therapy will be evaluated one week after stop of antibiotic therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of antibiotic</measure>
    <time_frame>participants will be followed for the duration of antibiotic therap, an expected average of 10 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Record the amount of antibiotic usage during antibiotic therapy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost of antibiotic therapy</measure>
    <time_frame>participants will be followed for the duration of antibiotic therapy, an expected average of 10 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Record the cost of antibiotic therapy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lower Respiratory Tract Infection</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Meropenem therapy with regimen routinely decided by attending physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in Study group will accept meropenem therapy based on PPK and PD parameter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem therapy based on  PPK  and PD</intervention_name>
    <description>Meropenem therapy with regimen decided by a software developed from a PPK model and clinical PD parameter</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Mepem, meropenem for injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients hospitalized at the Peking University Third Hospital with community-acquired
             or hospital-acquired lower respiratory tract infection.

          -  Sixty years and older.

        Exclusion Criteria:

          -  More than one pathogenic Gram-negative bacillus is isolated from tracheal aspirate or
             sputum culture

          -  younger than 60 years old

          -  Positive HIV antibody titre

          -  Had known or suspected tuberculosis or other infections caused by Gram-positive
             cocci, viruses or fungi at baseline.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingtao Zhou, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qingtao Zhou, MD</last_name>
    <phone>86-10-82265562</phone>
    <email>zhouqingtaobysy@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospita</name>
      <address>
        <city>Haidian District</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingtao Zhou, MD</last_name>
      <phone>86-10-82265562</phone>
      <email>zhouqingtaobysy@sina.com</email>
    </contact>
    <investigator>
      <last_name>Qingtao Zhou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 12, 2013</lastchanged_date>
  <firstreceived_date>July 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Third Hospital</investigator_affiliation>
    <investigator_full_name>Qingtao Zhou</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Infection; Meropenem; Pharmacokinetics; Pharmacodynamics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meropenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
